Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah F Andrews

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Science Translational Medicine|January 3, 2024
Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primatesMadhu Prabhakaran, Flavio Matassoli, David Leggat, et al.
Science Translational Medicine|September 10, 2025
Functional, immunogenetic, and structural convergence in influenza immunity between humans and macaquesMaya Sangesland, Ning Li, Yaroslav Tsybovsky, et al.
Nature Immunology|February 12, 2019
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responsesMasaru Kanekiyo, M Gordon Joyce, Rebecca A Gillespie, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
Functional, Immunogenetic, and Structural Convergence in Influenza Immunity between Humans and MacaquesMaya Sangesland, Ning Li, Yaroslav Tsybovsky, et al.
Nature Immunology|April 14, 2019
Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responsesMasaru Kanekiyo, M Gordon Joyce, Rebecca A Gillespie, et al.
Nature Microbiology|October 14, 2025
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza virusesAlexandra A Abu-Shmais, Gray Freeman, Adrian Creanga, et al.
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
NPJ Vaccines|September 17, 2024
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccineJoseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, et al.
Science (New York, N.Y.)|May 15, 2025
Precise targeting of HIV broadly neutralizing antibody precursors in humansTom G Caniels, Madhu Prabhakaran, Gabriel Ozorowski, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Science Translational Medicine|January 3, 2024
Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primatesMadhu Prabhakaran, Flavio Matassoli, David Leggat, et al.
Science Translational Medicine|September 10, 2025
Functional, immunogenetic, and structural convergence in influenza immunity between humans and macaquesMaya Sangesland, Ning Li, Yaroslav Tsybovsky, et al.
Nature Immunology|February 12, 2019
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responsesMasaru Kanekiyo, M Gordon Joyce, Rebecca A Gillespie, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
Functional, Immunogenetic, and Structural Convergence in Influenza Immunity between Humans and MacaquesMaya Sangesland, Ning Li, Yaroslav Tsybovsky, et al.
Nature Immunology|April 14, 2019
Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responsesMasaru Kanekiyo, M Gordon Joyce, Rebecca A Gillespie, et al.
Nature Microbiology|October 14, 2025
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza virusesAlexandra A Abu-Shmais, Gray Freeman, Adrian Creanga, et al.
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
NPJ Vaccines|September 17, 2024
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccineJoseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, et al.
Science (New York, N.Y.)|May 15, 2025
Precise targeting of HIV broadly neutralizing antibody precursors in humansTom G Caniels, Madhu Prabhakaran, Gabriel Ozorowski, et al.
Pageof 8